BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22897733)

  • 1. The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011).
    Solh M; Rai KR; Peterson BL; Kolitz JE; Appelbaum FR; Tallman MS; Belch A; Larson RA; Morrison VA
    Leuk Lymphoma; 2013 Feb; 54(2):252-4. PubMed ID: 22897733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Richter syndrome and fludarabine: a controversial relationship.
    Rossi D
    Leuk Lymphoma; 2013 Feb; 54(2):213-4. PubMed ID: 22897730
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
    Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
    J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of chronic lymphocytic leukaemia.
    Kalil N; Cheson BD
    Drugs Aging; 2000 Jan; 16(1):9-27. PubMed ID: 10733261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
    Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
    N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.
    Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Martell RE; Larson RA; Schiffer CA
    J Clin Oncol; 2001 Aug; 19(16):3611-21. PubMed ID: 11504743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infections in patients with chronic lymphocytic leukemia treated with fludarabine.
    Anaissie EJ; Kontoyiannis DP; O'Brien S; Kantarjian H; Robertson L; Lerner S; Keating MJ
    Ann Intern Med; 1998 Oct; 129(7):559-66. PubMed ID: 9758577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
    Byrd JC; Rai K; Peterson BL; Appelbaum FR; Morrison VA; Kolitz JE; Shepherd L; Hines JD; Schiffer CA; Larson RA
    Blood; 2005 Jan; 105(1):49-53. PubMed ID: 15138165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia.
    Kantarjian HM; Childs C; O'Brien S; Huh Y; Beran M; Schachner J; Koller C; Keating MJ
    Am J Med; 1991 Feb; 90(2):223-8. PubMed ID: 1996592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
    Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
    Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Richter syndrome with a monoclonal component from a true B-cell chronic lymphocytic leukemia (B-CLL) treated with fludarabine.
    Bernasconi P; Paulli M; Orlandi E; Perfetti V; Giardini I; Zibellini S; Vanelli L; Tenore AM; Algarotti A; Boni M; De Amici M; Brusamolino E; Lazzarino M
    Ann Hematol; 2007 Aug; 86(8):619-22. PubMed ID: 17356849
    [No Abstract]   [Full Text] [Related]  

  • 12. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
    O'Brien S; Kantarjian H; Beran M; Smith T; Koller C; Estey E; Robertson LE; Lerner S; Keating M
    Blood; 1993 Sep; 82(6):1695-700. PubMed ID: 8400226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia.
    Dearden C; Wade R; Else M; Richards S; Milligan D; Hamblin T; Catovsky D; ; ;
    Blood; 2008 Feb; 111(4):1820-6. PubMed ID: 18055869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
    Martell RE; Peterson BL; Cohen HJ; Petros WP; Rai KR; Morrison VA; Elias L; Shepherd L; Hines J; Larson RA; Schiffer CA; Hurwitz HI
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):37-45. PubMed ID: 12111110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
    Mulligan SP; Karlsson K; Strömberg M; Jønsson V; Gill D; Hammerström J; Hertzberg M; McLennan R; Uggla B; Norman J; Wallvik J; Sundström G; Johansson H; Brandberg Y; Liliemark J; Juliusson G;
    Leuk Lymphoma; 2014 Dec; 55(12):2769-77. PubMed ID: 24524339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
    Tsimberidou AM; O'Brien SM; Cortes JE; Faderl S; Andreeff M; Kantarjian HM; Keating MJ; Giles FJ
    Leuk Lymphoma; 2002 Apr; 43(4):767-72. PubMed ID: 12153163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.
    Bowen AL; Zomas A; Emmett E; Matutes E; Dyer MJ; Catovsky D
    Br J Haematol; 1997 Mar; 96(3):617-9. PubMed ID: 9054672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
    Keating MJ; O'Brien S; Lerner S; Koller C; Beran M; Robertson LE; Freireich EJ; Estey E; Kantarjian H
    Blood; 1998 Aug; 92(4):1165-71. PubMed ID: 9694704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
    Lanasa MC; Andritsos L; Brown JR; Gabrilove J; Caligaris-Cappio F; Ghia P; Larson RA; Kipps TJ; Leblond V; Milligan DW; Janssens A; Johnson AJ; Heerema NA; Bühler A; Stilgenbauer S; Devin J; Hallek M; Byrd JC; Grever MR
    Leuk Res; 2015 May; 39(5):495-500. PubMed ID: 25804339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.
    Chow KU; Kim SZ; von Neuhoff N; Schlegelberger B; Stilgenbauer S; Wunderle L; Cordes HJ; Bergmann L
    Eur J Haematol; 2011 Nov; 87(5):426-33. PubMed ID: 21749447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.